26 articles for TH Keller
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Structure-Activity Relationship Studies of Mitogen Activated Protein Kinase Interacting Kinase (MNK) 1 and 2 and BCR-ABL1 Inhibitors Targeting Chronic Myeloid Leukemic Cells.
Experimental Therapeutics Centre
The use of porcupine inhibitors to target Wnt-driven cancers.
Experimental Therapeutics Centre
Discovery and Optimization of 4-(8-(3-Fluorophenyl)-1,7-naphthyridin-6-yl)transcyclohexanecarboxylic Acid, an Improved PDE4 Inhibitor for the Treatment of Chronic Obstructive Pulmonary Disease (COPD).
Novartis Institutes For Biomedical Research
N-arylrolipram derivatives as potent and selective PDE4 inhibitors.
Novartis Horsham Research Center
Fragment-based ligand design of novel potent inhibitors of tankyrases.
Nanyang Technological University
Solubility-driven optimization of phosphodiesterase-4 inhibitors leading to a clinical candidate.
Novartis Institutes For Biomedical Research
Spirotetrahydro beta-carbolines (spiroindolones): a new class of potent and orally efficacious compounds for the treatment of malaria.
Novartis Institute For Tropical Diseases
Potent and selective xanthine-based inhibitors of phosphodiesterase 5.
Novartis Institutes of Biomedical Research
A new orally bioavailable dual adenosine A2B/A3 receptor antagonist with therapeutic potential.
Novartis Institutes For Biomedical Research
Preclinical evaluation of the antifolate QN254, 5-chloro- N'6'-(2,5-dimethoxy-benzyl)-quinazoline-2,4,6-triamine, as an antimalarial drug candidate.
Kenya Medical Research Institute/Wellcome Trust Collaborative Research Program
Spiroindolones, a potent compound class for the treatment of malaria.
Swiss Tropical and Public Health Institute
N-sulfonylanthranilic acid derivatives as allosteric inhibitors of dengue viral RNA-dependent RNA polymerase.
Novartis Institute For Tropical Diseases
Peptide deformylase inhibitors of Mycobacterium tuberculosis: synthesis, structural investigations, and biological results.
Novartis Institute For Tropical Diseases
Peptide inhibitors of dengue virus NS3 protease. Part 2: SAR study of tetrapeptide aldehyde inhibitors.
Novartis Institute For Tropical Diseases
Peptide inhibitors of Dengue virus NS3 protease. Part 1: Warhead.
Novartis Institute For Tropical Diseases
Fragment-based lead discovery of indazole-based compounds as AXL kinase inhibitors.
Experimental Drug Development Centre
Fragment-based Discovery of a Small-Molecule Protein Kinase C-iota Inhibitor Binding Post-kinase Domain Residues.
Astar
Discovery of Irreversible Inhibitors Targeting Histone Methyltransferase, SMYD3.
Experimental Drug Development Centre
Discovery of dual GyrB/ParE inhibitors active against Gram-negative bacteria.
Experimental Therapeutics Centre
Fragment-Based Drug Discovery of Potent Protein Kinase C Iota Inhibitors.
Agency For Science, Technology and Research (A*Star)
Scaffold Hopping and Optimization of Maleimide Based Porcupine Inhibitors.
Experimental Therapeutics Centre
BIPHENYL COMPOUND AS IMMUNOMODULATOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF
Shenzhen Chipscreen Biosciences